Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 have?
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 has 143 citations in the OpenAlex counts ScholarIQ stores.
When was Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 published?
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 has 2008 year in the ScholarIQ index.
What is the open-access status of Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148?
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 has bronze oa status in the ScholarIQ index.
What is the DOI of Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148?
The DOI for Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 is on the source record.
What is the PMID of Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148?
The PMID for Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 is on the source record.
What is the OpenAlex record for Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148?
The OpenAlex for Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148 is on the source record.